全球生物相似单株抗体市场规模、份额、趋势和成长分析报告（2026-2034）

预计生物类似单株抗体市场将从 2025 年的 170.1 亿美元成长到 2034 年的 1,072.9 亿美元，2026 年至 2034 年的复合年增长率为 22.71%。

随着医疗系统寻求生物製药疗法的替代方案，全球生物相似药单株抗体市场正经历强劲成长。生物相似药与原厂生物製药具有相当的安全性和有效性，使其成为治疗癌症和自体免疫疾病等慢性疾病的理想选择。多种重磅单株抗体专利的到期进一步加速了市场扩张。

关键成长要素包括医疗保健支出增加、有利的法规结构以及对价格合理的治疗方法的需求不断增长。慢性病盛行率上升和患者群不断扩大，正促使製药公司投资于生物相似药的研发。生物製程技术和生产能力的进步也提高了生产效率。

随着更多生物相似药在已开发市场和新兴市场获得监管部门核准，未来前景一片光明。日益激烈的竞争有望降低治疗成本，并改善患者获得先进疗法的机会。生物技术公司之间持续的研究合作和策略伙伴关係将增强产品管线，并确保生物类似单株抗体市场的可持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球生物相似单株抗体市场：按类型划分

• 市场分析、洞察与预测
• Adalimumab
• Bevacizumab
• Infliximab
• Rituximab
• 曲妥珠单抗
• 其他的

第五章：全球生物相似单株抗体市场：依适应症划分

• 市场分析、洞察与预测
• 肿瘤学
• 自体免疫疾病
• 其他的

第六章 全球生物相似单株抗体市场：依最终用户划分

• 市场分析、洞察与预测
• 医院
• 癌症治疗中心
• 其他的

第七章 全球生物相似单株抗体市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Teva Pharmaceutical Industries Limited
  • Coherus BioSciences Inc
  • Shanghai Henlius Biotech Inc
  • Celltrion Healthcare Co. Ltd
  • BIOCAD
  • Pfizer Inc
  • Amgen Inc
  • Biocon
  • Biogen
  • Novartis AG

The Biosimilar Monoclonal Antibody Market size is expected to reach USD 107.29 Billion in 2034 from USD 17.01 Billion (2025) growing at a CAGR of 22.71% during 2026-2034.

The Global Biosimilar Monoclonal Antibody Market is witnessing strong growth as healthcare systems seek cost-effective alternatives to expensive biologic therapies. Biosimilars offer similar safety and efficacy profiles compared to reference biologics, making them attractive options for treating chronic diseases such as cancer and autoimmune disorders. The expiration of patents for several blockbuster monoclonal antibodies has accelerated market expansion.

Key growth drivers include increasing healthcare expenditure, supportive regulatory frameworks, and rising demand for affordable biologic treatments. Growing prevalence of chronic diseases and expanding patient populations are encouraging pharmaceutical companies to invest in biosimilar development. Advances in bioprocessing technologies and manufacturing capabilities are also enhancing production efficiency.

Future prospects appear promising as more biosimilars gain regulatory approvals across developed and emerging markets. Increased competition is expected to reduce treatment costs and improve patient access to advanced therapies. Ongoing research collaborations and strategic partnerships among biotechnology firms will likely strengthen the pipeline, ensuring sustained growth in the biosimilar monoclonal antibody market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Adalimumab
• Bevacizumab
• Infliximab
• Rituximab
• Trastuzumab
• Others

By Indication

• Oncology
• Autoimmune Diseases
• Others

By End User

• Hospitals
• Cancer Treatment Centers
• Others

COMPANIES PROFILED

• Teva Pharmaceutical Industries Limited, Coherus BioSciences Inc, Shanghai Henlius Biotech Inc, Celltrion Healthcare Co Ltd, BIOCAD, Pfizer Inc, Amgen Inc, Biocon, Biogen, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Adalimumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Bevacizumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Infliximab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Rituximab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Trastuzumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer Treatment Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Indication
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Indication
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Indication
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Indication
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Indication
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Teva Pharmaceutical Industries Limited
  • 9.2.2 Coherus BioSciences Inc
  • 9.2.3 Shanghai Henlius Biotech Inc
  • 9.2.4 Celltrion Healthcare Co. Ltd
  • 9.2.5 BIOCAD
  • 9.2.6 Pfizer Inc
  • 9.2.7 Amgen Inc
  • 9.2.8 Biocon
  • 9.2.9 Biogen
  • 9.2.10 Novartis AG